Overview

Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients

Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of posaconazole as prophylaxis antifungal agent in aplastic anemia / hypoplastic myelodysplastic syndrome (AA/hMDS) patients undergoing antithymocyte globulin (ATG) treatment
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Antifungal Agents
Antilymphocyte Serum
Posaconazole